NCT03143855View on ClinicalTrials.gov

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 30, 2017

Primary Completion Date

April 5, 2019

Study Completion Date

April 5, 2019

Conditions
Opioid AbuseOpioid DependenceOpioid-Related DisordersOpioid Use
Interventions
DRUG

Lorcaserin

Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days

DRUG

Placebo

Placebo will be administered twice daily for for 5 days

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Virginia Commonwealth University

OTHER

NCT03143855 - Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder | Biotech Hunter | Biotech Hunter